Inbound marketing is often explained using standard B2B assumptions: defined funnels, steady lead flow, and relatively short paths from first touchpoint to conversion.
Biotech companies operate differently.
Products and services are more complex, target groups are more specialised, and decision-making processes tend to take longer. Content needs to be technically accurate, and credibility plays a central role throughout the entire process.
That doesn’t make inbound marketing less relevant. If anything, it increases its importance. But it does change how it should be approached, how long it takes to see results, and how resources need to be allocated.
This article outlines what biotech companies should realistically expect to invest in inbound marketing, and how that differs from more general B2B contexts.
Inbound marketing is not a campaign that runs for a few months. It is a structured process that builds over time.
It typically consists of three parts:
The first step is developing a structured inbound marketing strategy.
In standard B2B, this usually includes defining buyer personas and mapping the customer journey. In biotech, this needs to be more specific.
Target groups are often clearly differentiated:
Scientific users evaluating technical fit
R&D or innovation leads
Business development teams
Procurement or operational stakeholders
Each of these groups has different expectations in terms of content, level of detail, and decision criteria.
A solid strategy phase typically includes:
Defining target audiences and personas
Mapping the customer journey across multiple stakeholders
Identifying relevant topics and use cases
Selecting appropriate channels and tools
Defining measurable goals and KPIs
For biotech companies, this phase is particularly important because positioning is often closely tied to scientific differentiation. If that is not clearly translated into accessible messaging, later activities lose effectiveness.
Typical investment of approx. €7,000 (±20%, depending on scope and complexity) should be expected.
A good inbound marketing strategy helps attracts leads, yes.
But how do you qualify, segment and follow up with these leads? Find out here:
Once the strategy is defined, the next step is implementation.
This includes setting up the systems and structures required to run inbound marketing effectively.
Typical components:
Website adjustments or restructuring
SEO foundation (including technical setup and keyword structure)
CRM and marketing automation tools
Analytics and reporting setup
In biotech, setup often requires additional consideration.
Content is usually more technical, and users may not convert directly after a single interaction. That means:
Conversion paths need to be more gradual
Different types of content need to be integrated (e.g. educational and technical materials)
Tracking needs to capture longer and more complex engagement patterns
Many companies discover at this stage that their existing website or systems are not designed for inbound marketing and require adjustment.
Typical investment:
Approx. €9,500 on average
Realistic range: €5,000 to €15,000+ depending on scope and tools
The third component is the continuous execution of inbound marketing activities.
This is where most of the long-term investment lies.
Inbound marketing follows a recurring cycle:
Planning
Content creation and implementation
Measurement and analysis
Iterative improvement
This cycle is repeated continuously, often in quarterly (90-day) phases.
Typical activities include:
Content creation (e.g. articles, case studies, technical content)
Search engine optimization
Marketing automation workflows
Performance analysis and reporting
Ongoing refinement of topics and formats
For biotech companies, execution differs mainly in terms of content requirements.
Content typically needs:
Greater technical accuracy
Closer collaboration with internal experts
More detailed explanation of use cases
Stronger emphasis on credibility and validation
This usually results in longer production cycles and higher effort per piece of content compared to general B2B marketing.
Typical investment estimated per month for external support at approx. €5,000 per month for external support.
Lower budgets are possible but typically subject to reduced output and tend to slow down progress accordingly.
Beyond the three main components, additional costs may apply.
These can include:
Marketing software (e.g. CRM and automation platforms)
Paid campaigns (e.g. search or social advertising)
These are not part of the core inbound budget but are often necessary depending on the company’s starting point and growth goals.
Inbound marketing in biotech can’t be evaluated using short-term lead volume alone.
More relevant indicators include:
Visibility in relevant search areas
Engagement from the right target groups
Development of qualified opportunities over time
Improved understanding of audience interests and behaviour
Given longer sales cycles, results often develop gradually rather than immediately.
A realistic inbound marketing setup for a biotech company typically includes:
Strategy: approx. €7,000 (±20%)
Setup: approx. €9,500 (typically between €5,000 and €15,000+)
Ongoing execution: approx. €5,000 per month
Additional costs: software and optional paid media
Beyond budget, successful implementation depends on:
Clear positioning
Consistent execution
Collaboration between marketing and technical teams
Inbound marketing is most effective when it is treated as a structured, long-term process rather than a short-term initiative.
If you’re currently evaluating inbound marketing for your biotech company, we’re happy to walk through what this could look like for your specific situation.
In our call, we can evaluate with you: